Capricor TherapeuticsCAPR just hit that mark, with a jump from 69 to 86 Thursday. Please watch the video at Investors.com - ...

Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will become the first approved treatment for cardiomyopathy associated with ...

Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease ...

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results ...

CAPR | Complete Capricor Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

Capricor Therapeutics, Inc. (CAPR) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...